+关注
Retailer
暂无个人介绍
IP属地：未知
23
关注
2
粉丝
0
主题
0
勋章
主贴
热门
Retailer
2021-10-20
Thank you for sharinf
抱歉，原内容已删除
Retailer
2021-10-03
Thanks , added Veeva in my watchlist
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3586754499068036,"uuid":"3586754499068036","gmtCreate":1623667430635,"gmtModify":1626415823372,"name":"Retailer","pinyin":"retailer","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5ad4e71e4667e8585882bc3b08fd0845","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":23,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":859695039,"gmtCreate":1634690870572,"gmtModify":1634690870688,"author":{"id":"3586754499068036","authorId":"3586754499068036","name":"Retailer","avatar":"https://static.tigerbbs.com/5ad4e71e4667e8585882bc3b08fd0845","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thank you for sharinf","listText":"Thank you for sharinf","text":"Thank you for sharinf","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859695039","repostId":"2175144894","repostType":2,"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867838856,"gmtCreate":1633235014714,"gmtModify":1633235014714,"author":{"id":"3586754499068036","authorId":"3586754499068036","name":"Retailer","avatar":"https://static.tigerbbs.com/5ad4e71e4667e8585882bc3b08fd0845","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thanks , added Veeva in my watchlist","listText":"Thanks , added Veeva in my watchlist","text":"Thanks , added Veeva in my watchlist","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867838856","repostId":"2172964534","repostType":4,"isVote":1,"tweetType":1,"viewCount":1069,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":867838856,"gmtCreate":1633235014714,"gmtModify":1633235014714,"author":{"id":"3586754499068036","authorId":"3586754499068036","name":"Retailer","avatar":"https://static.tigerbbs.com/5ad4e71e4667e8585882bc3b08fd0845","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thanks , added Veeva in my watchlist","listText":"Thanks , added Veeva in my watchlist","text":"Thanks , added Veeva in my watchlist","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867838856","repostId":"2172964534","repostType":4,"repost":{"id":"2172964534","pubTimestamp":1633221732,"share":"https://www.laohu8.com/m/news/2172964534?lang=&edition=full","pubTime":"2021-10-03 08:42","market":"us","language":"en","title":"2 Leading Healthcare Stocks to Buy in 2021 and Beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2172964534","media":"Motley Fool","summary":"The future looks bright with these two supercharged stocks.","content":"<p>If you're looking for new stocks to add to your portfolio that can generate sustained growth and keep generating returns in all kinds of markets, <a href=\"https://laohu8.com/S/AONE.U\">one</a> excellent industry to look at is healthcare. While not all stocks in this sector perform the same in turbulent markets, many do provide products and services that customers need regardless of the economy -- and this can lend resilience to a long-term investor's portfolio.</p>\n<p>To that end, today, we're going to take a look at two high-growth companies in the healthcare space. One is a leader in medical robotics while the other helps healthcare companies run their businesses more efficiently. Let's get started.</p>\n<p><img src=\"https://static.tigerbbs.com/bc209e3e1fc5ad6f0407e698d4c85f5c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h2>1. Intuitive Surgical</h2>\n<p>Medical robotics pioneer<b> Intuitive Surgical</b> (NASDAQ:ISRG) was founded in 1995 and has been a publicly traded entity for more than two decades. Since the IPO, its shares have skyrocketed more than 16,000%. In the past year alone, the stock is up more than 40%. With its shares now trading just shy of $1,000, it's no surprise that the company is planning to undergo a stock split in early October.</p>\n<p>The stock has soared for good reason. Intuitive dominates the global surgical robotics market (more than three-quarters of it, in fact), most notably with its da Vinci Surgical System. Its approach has become more and more widely accepted -- and so Intuitive's revenue over the past decade has grown nearly 150% while net income has risen about 114%.</p>\n<p>And the company is just getting started. The global surgical robotics industry is expected to grow exponentially in the years ahead as an increasing number of medical providers utilize these tools in minimally invasive procedures due to their efficiency, accuracy, and ability to generate more positive post-surgery outcomes, such as shorter inpatient care.</p>\n<p>An investment in Intuitive Surgical could generate sustained returns for many years as it expands its footprint in this multi-billion-dollar industry and as reliance on surgical robotics continues to grow.</p>\n<h2>2. Veeva Systems</h2>\n<p>Cloud solutions provider <b>Veeva Systems</b> (NYSE:VEEV) may not be a name that immediately comes to mind when thinking about the healthcare sector, but it's a compelling choice for long-term investors to consider. The company helps healthcare companies -- ranging from household-name pharmaceutical giants to smaller life sciences entities -- effectively store their information.</p>\n<p>Veeva clients seem to appreciate what they do. The company has a long and respectable history of growth, having increased revenue more than 160% and net income nearly 390% over the past five years.</p>\n<p>And the company remains on track. For the first half of its fiscal 2022 (ended Jul. 31), Veeva reported a revenue increase of about 29% from the year-ago period. This was driven by a 28% boost in its subscription services as well as a 33% increase in its professional and other services. Net income increased about 25% during the same time period.</p>\n<p>Veeva's stock isn't cheap, trading at around $285 a share and a price-to-sales (P/S) ratio of about 26. But it's also safe to say that these kinds of valuations are something investors have come to expect from stocks in the high-growth SaaS space. Shares of the company have consistently appreciated over the years -- and even at its current premium valuation, Wall Street thinks the stock has upside of as much as 40% over the next 12 months.</p>\n<p>Finally, demand for Veeva's products and services isn't likely going anywhere, and its list of customers -- including such big names as <b>Merck</b>, <b>Eli Lilly</b>, and <b>Bayer </b>-- is only growing. Veeva Systems is a stock for the long haul. And if you're not thrilled about its current price, there's no harm in dipping your toe by investing in fractional shares of this stock for now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Leading Healthcare Stocks to Buy in 2021 and Beyond</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Leading Healthcare Stocks to Buy in 2021 and Beyond\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-03 08:42 GMT+8 <a href=https://www.fool.com/investing/2021/10/02/2-leading-healthcare-stocks-buy-in-2021-and-beyond/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you're looking for new stocks to add to your portfolio that can generate sustained growth and keep generating returns in all kinds of markets, one excellent industry to look at is healthcare. While...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/02/2-leading-healthcare-stocks-buy-in-2021-and-beyond/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/02/2-leading-healthcare-stocks-buy-in-2021-and-beyond/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172964534","content_text":"If you're looking for new stocks to add to your portfolio that can generate sustained growth and keep generating returns in all kinds of markets, one excellent industry to look at is healthcare. While not all stocks in this sector perform the same in turbulent markets, many do provide products and services that customers need regardless of the economy -- and this can lend resilience to a long-term investor's portfolio.\nTo that end, today, we're going to take a look at two high-growth companies in the healthcare space. One is a leader in medical robotics while the other helps healthcare companies run their businesses more efficiently. Let's get started.\n\nImage source: Getty Images.\n1. Intuitive Surgical\nMedical robotics pioneer Intuitive Surgical (NASDAQ:ISRG) was founded in 1995 and has been a publicly traded entity for more than two decades. Since the IPO, its shares have skyrocketed more than 16,000%. In the past year alone, the stock is up more than 40%. With its shares now trading just shy of $1,000, it's no surprise that the company is planning to undergo a stock split in early October.\nThe stock has soared for good reason. Intuitive dominates the global surgical robotics market (more than three-quarters of it, in fact), most notably with its da Vinci Surgical System. Its approach has become more and more widely accepted -- and so Intuitive's revenue over the past decade has grown nearly 150% while net income has risen about 114%.\nAnd the company is just getting started. The global surgical robotics industry is expected to grow exponentially in the years ahead as an increasing number of medical providers utilize these tools in minimally invasive procedures due to their efficiency, accuracy, and ability to generate more positive post-surgery outcomes, such as shorter inpatient care.\nAn investment in Intuitive Surgical could generate sustained returns for many years as it expands its footprint in this multi-billion-dollar industry and as reliance on surgical robotics continues to grow.\n2. Veeva Systems\nCloud solutions provider Veeva Systems (NYSE:VEEV) may not be a name that immediately comes to mind when thinking about the healthcare sector, but it's a compelling choice for long-term investors to consider. The company helps healthcare companies -- ranging from household-name pharmaceutical giants to smaller life sciences entities -- effectively store their information.\nVeeva clients seem to appreciate what they do. The company has a long and respectable history of growth, having increased revenue more than 160% and net income nearly 390% over the past five years.\nAnd the company remains on track. For the first half of its fiscal 2022 (ended Jul. 31), Veeva reported a revenue increase of about 29% from the year-ago period. This was driven by a 28% boost in its subscription services as well as a 33% increase in its professional and other services. Net income increased about 25% during the same time period.\nVeeva's stock isn't cheap, trading at around $285 a share and a price-to-sales (P/S) ratio of about 26. But it's also safe to say that these kinds of valuations are something investors have come to expect from stocks in the high-growth SaaS space. Shares of the company have consistently appreciated over the years -- and even at its current premium valuation, Wall Street thinks the stock has upside of as much as 40% over the next 12 months.\nFinally, demand for Veeva's products and services isn't likely going anywhere, and its list of customers -- including such big names as Merck, Eli Lilly, and Bayer -- is only growing. Veeva Systems is a stock for the long haul. And if you're not thrilled about its current price, there's no harm in dipping your toe by investing in fractional shares of this stock for now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1069,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859695039,"gmtCreate":1634690870572,"gmtModify":1634690870688,"author":{"id":"3586754499068036","authorId":"3586754499068036","name":"Retailer","avatar":"https://static.tigerbbs.com/5ad4e71e4667e8585882bc3b08fd0845","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Thank you for sharinf","listText":"Thank you for sharinf","text":"Thank you for sharinf","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859695039","repostId":"2175144894","repostType":2,"repost":{"id":"2175144894","pubTimestamp":1634516009,"share":"https://www.laohu8.com/m/news/2175144894?lang=&edition=full","pubTime":"2021-10-18 08:13","market":"sh","language":"zh","title":"英美烟草：低回报率市场下的高股息股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2175144894","media":"智通财经APP","summary":"尽管利率可能在2022年的某个时候上升，但对于收益导向型投资者来说，债券或债券替代品中高于平均回报率的选择仍然很少：标普500指数目前的回报率为1.3%，ProShares标普500股利贵族ETF回报率为1.9%，公用事业指数ETF-SPDR回报率为3.1%。如果投资者不抗拒烟草股，并且希望当前将收益最大化，或许英美烟草是值得考虑的选择。英美烟草的下一代产品有望吸引千禧一代和X一代的消费者，这将在公司的整体收入构成中占越来越大的比例。","content":"<p>尽管利率可能在2022年的某个时候上升，但对于收益导向型投资者来说，债券或债券替代品中高于平均回报率的选择仍然很少：标普500指数(SPY.US)目前的回报率为1.3%，ProShares标普500股利贵族ETF(NOBL.US)回报率为1.9%，公用事业指数ETF-SPDR(XLU.US)回报率为3.1%。</p>\n<p>然而，如果投资者能够从一家内在价值高、收入基础稳固且持续增长的公司获得8.6%的回报率，那是否值得考虑呢?如果投资者不抗拒烟草股，并且希望当前将收益最大化，或许<a href=\"https://laohu8.com/S/BTI\">英美烟草</a>是值得考虑的选择。</p>\n<p>财务分析</p>\n<p>首先，从财务表现方面看，在过去五年中，英美烟草的营收持续增长，不过，考虑到烟草产品在美国并不受欢迎，这一增长对美国投资者来说似乎是一种反常现象。<img src=\"https://static.tigerbbs.com/18dc5b6d6261424bb7915ab1643dcd66\" tg-width=\"748\" tg-height=\"506\" referrerpolicy=\"no-referrer\">但对于全世界而言，许多其他国家的烟草使用并没有下降，反而是在增加。英美烟草实在土耳其和巴西等其他国家的营收实现强劲增长。同时，随着孟加拉国、墨西哥、越南和俄罗斯的销量增长，该公司在新兴市场的业务也将随之增长，这些海外市场的营收增长将有助于抵消该公司在其他地区可燃产品销售减少的影响。</p>\n<p>虽然英美烟草目前通过其传统烟草产品(尤其是在新兴市场)创造了丰厚的营收，但其长期增长潜力在于不可燃产品，如加热烟草和蒸汽技术产品。英美烟草的下一代产品有望吸引千禧一代和X一代的消费者，这将在公司的整体收入构成中占越来越大的比例。</p>\n<p>另外，英美烟草正致力于将自己从一家可燃烟草制品公司转变为一家多品类消费品公司。正如上图所示，英美烟草的新业务增长是显而易见的，过去五年其营收也几乎实现翻番。</p>\n<p>例如，在10月12日，英美烟草取得一项重要进展：美国食品和药物管理局(FDA)批准公司销售其Vuse Solo电子烟和豆荚烟弹，使其成为首个获得卫生监管机构批准的蒸汽产品。这对于所谓的“罪恶股票”(Sin Stock、在美国,涉及烟草、酒精、博彩和军火生产的股票被称为“罪恶股票”)以及其竞争对手来说意义重大，因为美国主要的卫生监管机构通过批准非传统产品，似乎已经证实了其投资理论。</p>\n<p>而从该公司稳定的营收流和运营资本来看，可燃传统烟草产品也将为该公司下一代非可燃产品提供资金支持。</p>\n<p>不过，该公司有一个财务指标令人担忧：相对较高的债务负担。下图清楚地显示了其长期负债的扩大。<img src=\"https://static.tigerbbs.com/4a54c76e66685e5fa739b341ae6e1b24\" tg-width=\"770\" tg-height=\"491\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/84e29f8edb8ea211e414eb4fa9684434\" tg-width=\"747\" tg-height=\"491\" referrerpolicy=\"no-referrer\"></p>\n<p>英美烟草在2017年以860亿美元收购雷诺兹烟草公司(Reynolds America)后，债务负担相当沉重。该公司债务负担的大幅增加反映在1.32的糟糕Altman-Z分数上(Altman-Z分数是由一家公司的“信用强度”测试的输出,该模型评估了上市公司有无破产的可能性)。该公司在其他债务和长期负债指标方面得分很低，在烟草制品行业统计的37家公司中，以债务股本比排名，低于78.38%的公司。行业中值为0.06，而英美烟草的比率为0.72。</p>\n<p>此外，在烟草制品行业的34家公司中，该公司的利息保障倍数排名低于82.35%的公司。行业中值为25.66，而英美烟草的比率为5.6。</p>\n<p>不过，这家烟草巨头有利的自由现金流指数抵消了沉重的债务负担，远远优于其行业竞争对手。</p>\n<p>英美烟草38%的运营利润率也高于同行业85%的公司，盈利能力在统计的10个公司中排名第8。</p>\n<p>还有就是，该公司在股价与自由现金流比率基础上统计得分中较高，排名高于80%的烟草制品行业公司。行业最大值为60.08，中值为14.62，最小值为3.79。英美烟草的比率为7.57。</p>\n<p>在股息覆盖率和潜在增长方面，虽然令人垂涎的高股息率非常吸引，但投资者依然需关注该股的股息是否稳定。英美烟草的派息率仅为65%，而竞争对手<a href=\"https://laohu8.com/S/MO\">奥驰亚</a>(MO.US)和<a href=\"https://laohu8.com/S/PM\">菲利普莫里斯</a>(PM.US)的派息率分别为78%和82%。</p>\n<p>估值分析</p>\n<p>在估值方面，尽管与竞争对手相比，英美烟草的长期负债相对较高，但按该公司目前36.10美元的股价计算，该股的价值被小幅低估了。</p>\n<p><img src=\"https://static.tigerbbs.com/96d68fa31b30952e428d00de319201ac\" tg-width=\"760\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/00140a7d79eb38347ce3577737eec711\" tg-width=\"876\" tg-height=\"635\" referrerpolicy=\"no-referrer\">根据其他几个指标，也可以表明英美烟草的当前股价低于其内在价值。例如，该公司的运营利润率已经扩大，但市净率接近10年低点，市盈率接近2年低点，目前36.10美元的股价接近10年低点，市销率接近10年低点。</p>\n<p>总结</p>\n<p>综上所述，在公司未来发展趋势稳定下，拥有高股息率的英美烟草或是期望在近期获得高收益、并在中期内实现价格升值的价值投资者的选择。</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英美烟草：低回报率市场下的高股息股票</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英美烟草：低回报率市场下的高股息股票\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-18 08:13 北京时间 <a href=https://finance.sina.com.cn/stock/usstock/c/2021-10-16/doc-iktzscyy0060650.shtml><strong>智通财经APP</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>尽管利率可能在2022年的某个时候上升，但对于收益导向型投资者来说，债券或债券替代品中高于平均回报率的选择仍然很少：标普500指数(SPY.US)目前的回报率为1.3%，ProShares标普500股利贵族ETF(NOBL.US)回报率为1.9%，公用事业指数ETF-SPDR(XLU.US)回报率为3.1%。\n然而，如果投资者能够从一家内在价值高、收入基础稳固且持续增长的公司获得8.6%的回报率，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-10-16/doc-iktzscyy0060650.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","relate_stocks":{"BTI":"英美烟草"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-10-16/doc-iktzscyy0060650.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2175144894","content_text":"尽管利率可能在2022年的某个时候上升，但对于收益导向型投资者来说，债券或债券替代品中高于平均回报率的选择仍然很少：标普500指数(SPY.US)目前的回报率为1.3%，ProShares标普500股利贵族ETF(NOBL.US)回报率为1.9%，公用事业指数ETF-SPDR(XLU.US)回报率为3.1%。\n然而，如果投资者能够从一家内在价值高、收入基础稳固且持续增长的公司获得8.6%的回报率，那是否值得考虑呢?如果投资者不抗拒烟草股，并且希望当前将收益最大化，或许英美烟草是值得考虑的选择。\n财务分析\n首先，从财务表现方面看，在过去五年中，英美烟草的营收持续增长，不过，考虑到烟草产品在美国并不受欢迎，这一增长对美国投资者来说似乎是一种反常现象。但对于全世界而言，许多其他国家的烟草使用并没有下降，反而是在增加。英美烟草实在土耳其和巴西等其他国家的营收实现强劲增长。同时，随着孟加拉国、墨西哥、越南和俄罗斯的销量增长，该公司在新兴市场的业务也将随之增长，这些海外市场的营收增长将有助于抵消该公司在其他地区可燃产品销售减少的影响。\n虽然英美烟草目前通过其传统烟草产品(尤其是在新兴市场)创造了丰厚的营收，但其长期增长潜力在于不可燃产品，如加热烟草和蒸汽技术产品。英美烟草的下一代产品有望吸引千禧一代和X一代的消费者，这将在公司的整体收入构成中占越来越大的比例。\n另外，英美烟草正致力于将自己从一家可燃烟草制品公司转变为一家多品类消费品公司。正如上图所示，英美烟草的新业务增长是显而易见的，过去五年其营收也几乎实现翻番。\n例如，在10月12日，英美烟草取得一项重要进展：美国食品和药物管理局(FDA)批准公司销售其Vuse Solo电子烟和豆荚烟弹，使其成为首个获得卫生监管机构批准的蒸汽产品。这对于所谓的“罪恶股票”(Sin Stock、在美国,涉及烟草、酒精、博彩和军火生产的股票被称为“罪恶股票”)以及其竞争对手来说意义重大，因为美国主要的卫生监管机构通过批准非传统产品，似乎已经证实了其投资理论。\n而从该公司稳定的营收流和运营资本来看，可燃传统烟草产品也将为该公司下一代非可燃产品提供资金支持。\n不过，该公司有一个财务指标令人担忧：相对较高的债务负担。下图清楚地显示了其长期负债的扩大。\n英美烟草在2017年以860亿美元收购雷诺兹烟草公司(Reynolds America)后，债务负担相当沉重。该公司债务负担的大幅增加反映在1.32的糟糕Altman-Z分数上(Altman-Z分数是由一家公司的“信用强度”测试的输出,该模型评估了上市公司有无破产的可能性)。该公司在其他债务和长期负债指标方面得分很低，在烟草制品行业统计的37家公司中，以债务股本比排名，低于78.38%的公司。行业中值为0.06，而英美烟草的比率为0.72。\n此外，在烟草制品行业的34家公司中，该公司的利息保障倍数排名低于82.35%的公司。行业中值为25.66，而英美烟草的比率为5.6。\n不过，这家烟草巨头有利的自由现金流指数抵消了沉重的债务负担，远远优于其行业竞争对手。\n英美烟草38%的运营利润率也高于同行业85%的公司，盈利能力在统计的10个公司中排名第8。\n还有就是，该公司在股价与自由现金流比率基础上统计得分中较高，排名高于80%的烟草制品行业公司。行业最大值为60.08，中值为14.62，最小值为3.79。英美烟草的比率为7.57。\n在股息覆盖率和潜在增长方面，虽然令人垂涎的高股息率非常吸引，但投资者依然需关注该股的股息是否稳定。英美烟草的派息率仅为65%，而竞争对手奥驰亚(MO.US)和菲利普莫里斯(PM.US)的派息率分别为78%和82%。\n估值分析\n在估值方面，尽管与竞争对手相比，英美烟草的长期负债相对较高，但按该公司目前36.10美元的股价计算，该股的价值被小幅低估了。\n根据其他几个指标，也可以表明英美烟草的当前股价低于其内在价值。例如，该公司的运营利润率已经扩大，但市净率接近10年低点，市盈率接近2年低点，目前36.10美元的股价接近10年低点，市销率接近10年低点。\n总结\n综上所述，在公司未来发展趋势稳定下，拥有高股息率的英美烟草或是期望在近期获得高收益、并在中期内实现价格升值的价值投资者的选择。","news_type":1},"isVote":1,"tweetType":1,"viewCount":523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
